Hepatitis B immune globulin - Biotest Pharmaceuticals

Drug Profile

Hepatitis B immune globulin - Biotest Pharmaceuticals

Alternative Names: HBVIg - Biotetst Pharmaceuticals; HBVIg - Nabi Biopharmaceuticals; HEBIG; Hepatitis B immune globulin-human - Biotest Pharmaceuticals; Human hepatitis B immunoglobulin - Biotest Pharmaceuticals; Nabi-HB

Latest Information Update: 09 Apr 2015

Price : $50

At a glance

  • Originator Nabi Biopharmaceuticals
  • Developer Biotest Pharmaceuticals
  • Class Antivirals; Immunoglobulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatitis B
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis B

Most Recent Events

  • 09 Apr 2015 No recent reports of development identified - Preregistration for Hepatitis B (Prevention of relapse) in USA (IV)
  • 04 Dec 2007 Nabi Pharmaceuticals' Biologics business unit has been acquired by Biotest Pharmaceuticals
  • 07 Sep 2006 Nabi Biopharmaceuticals obtained the exclusive worldwide rights to use a novel hyperimmune immunoglobulin extraction technology from ProMetic Life
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top